The polypill for cardiovascular disease prevention: pitfall or panacea?

Abstract

Get full access to this article

View all access options for this article.

References

BHF, Cardio & Vascular Coalition. (2008). Modelling the UK burden of cardiovascular disease to 2020. Retrieved from www.bhf.org.uk/plugins/PublicationsSearchResults/DownloadFile.aspx?docid=ad18e5a0-7da6-4c7c-8142-f68f27cde451&version=-1&title=Modelling+the+Burden+of+Cardiovascular+Disease+to+2020&resource=Z154.

BHF, Health Promotion Research Group. (2012). Coronary heart disease statistics: A compendium of health statistics. Retrieved from www.bhf.org.uk/publications/view-publication.aspx?ps=1002097.

Elley

C. R.

Gupta

A. K.

Webster

Selak

Jun

Patel

Thom

(2012) The efficacy and tolerability of ‘polypill’: Meta-analysis of randomized controlled trials. PLoS ONE 7(12): e52145–e52145. doi: 10.1371/journal.pone.0052145.

Gallagher, J. (2012). Polypill 'could save thousands' of lives. BBC News. Retrieved from www.bbc.co.uk/news/health-18883163.

Kmietowicz

(2013) Polypill inventor puts product online after failing to get backing from industry. British Medical Journal 346: f3991–f3991. doi: 10.1136/bmj.f3991.

Marshall

I. J.

Wolfe

C. D. A.

Mckevitt

(2012) Lay perspectives on hypertension and drug adherence: Systematic review of qualitative research. British Medical Journal 344: e3953–e3953. doi: 10.1136/bmj.e3953.

NICE. (2008). Identifying and supporting people most at risk of dying early. Retrieved from www.nice.org.uk/nicemedia/live/12068/42086/42086.pdf.

NICE. (2009). Medicine adherence. Retrieved from www.nice.org.uk/nicemedia/live/11766/43042/43042.pdf.

Office of National Statistics. (2012). Avoidable mortality in England and Wales 2010. Retrieved from www.ons.gov.uk/ons/dcp171778_264958.pdf.

10.

PILL Collaborative Group. (2011) An international randomized placebo-controlled trial of a four component combination pill (“polypill”) in people with raised cardio-vascular risk. PLoS ONE 6(5): e19857–e19857. doi: 10.1371/journal.pone.0019857.

11.

Thom

Poulter

Field

Patel

Prabhakaran

Stanton

Rodgers

(2013) Effects of fixed dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. Journal of American Medical Association 310(9): 918–929. doi: 10.1001/jama.2013.277064.

12.

TIPS. (2009) Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease. A phase II, double blinded, randomized trial. The Lancet 373: 1341–1351. doi: 10.1016/S0140-6736(09)60611-5.

13.

Viera

A. J.

Sheridan

S. L.

Edwards

Soliman

E. L.

Harris

Furberg

C. D.

(2011) Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Preventative Medicine 52(1): 10–15. doi: 10.1016/j.ypmed.2010.09.016.

14.

Virdee

S. K.

Greenfield

S. M.

Fletcher

Mcmanus

R. J.

Hobbs

F. D.

Mant

(2013) Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open 3: e002498–e002498. doi: 10.1136/bmjopen-2012-002498.

15.

Wald

D. S.

Morris

J. K.

Wald

N. J.

(2012) Randomised polypill crossover trial in people aged over 50 and over. PLoS ONE 7(7): e41297–e41297. doi: 10.1371/journal.pone.0041297.

16.

Wald

D. S.

Wald

N. J.

(2012) Implementation of a simple age-based strategy in the prevention of cardiovascular disease: The polypill approach. Journal of Evaluation in Clinical Practice 18(3): 612–615. doi: 10.1111/j.1365-2753.2011.01637.x.

17.

Wald

N. J.

Law

M. R.

(2003) A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal 326: 1419–1424. doi: 10.1136/bmj.326.7404.1419.

18.

WHO. (2003). Adherence to long-term therapies, evidence for action. Retrieved from www.who.int/chp/knowledge/publications/adherence_report/en/.

19.

WHO. (2013). Cardiovascular diseases. Fact sheet no. 317. Retrieved from www.who.int/mediacentre/factsheets/fs317/en/index.html.